JAPEX Shares Drop as Middle East Tensions Drive LNG Costs and Production Risks 
Want to cut your energy bills? Here’s how five experts are doing it 
Amazon Expands AI Bet with Up to $25 Billion Investment in Anthropic 
Nvidia Pushes 800V Data Center Power Systems to Boost Efficiency and Cut Costs 
Rising Jet Fuel Costs from Iran Conflict Push Airfare Higher Across Europe 
Tesla Q1 Earnings Preview: Robotaxi Delays and SpaceX Merger Speculation Grow 
China Food Delivery Stocks Dip as Regulators Crack Down on “Ghost Deliveries” 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Eli Lilly in Talks to Acquire Kelonia Therapeutics for Over $2 Billion 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
Samsung Boosts DRAM Supply to Tesla as AI-Driven Memory Demand Surges 
SK Hynix Launches 192GB SOCAMM2 Memory for Nvidia’s Next-Gen AI Chips 
Ethiopian Airlines Expands Fleet with New Boeing 787 Dreamliner Order to Boost Global Routes 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
VANCOUVER, British Columbia and CAMBRIDGE, Mass., March 08, 2017 -- Novelion Therapeutics, Inc. (NASDAQ:NVLN) (TSX:NVLN), a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases, announced today that the company will participate in the 29th Annual ROTH Conference. Chief Executive Officer Mary Szela is scheduled to present on Tuesday, March 14, 2017 at 2:00 p.m. PDT (5:00 p.m. EDT).
The presentation will be webcast live and may be accessed for up to 90 days following the conference by visiting the “Investors” section of Novelion’s website, www.novelion.com.
About Novelion Therapeutics
Novelion Therapeutics is a biopharmaceutical company dedicated to developing new standards of care for individuals living with rare diseases. Novelion has a diversified commercial portfolio through its indirect subsidiary, Aegerion Pharmaceuticals, Inc., which includes MYALEPT® and JUXTAPID®, and is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes. The company seeks to advance its portfolio of rare disease therapies by investing in science and clinical development.
CONTACT: Amanda Murphy, Director, Investor Relations & Corporate Communications Novelion Therapeutics 857-242-5024 [email protected]
